Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076771 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wulin Long und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry, Sichuan University, Chengdu 610064, China. Hauptthemen laut MEDLINE: Torsades de Pointes, Long QT Syndrome, Adverse Outcome Pathways, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In pharmaceutical treatment, many non-cardiac drugs carry the risk of prolonging the QT interval, which can lead to fatal cardiac complications such as torsades de points (TdP). Although the unexpected blockade of ion channels has been widely considered to be one of the main reasons for affecting the repolarization phase of the cardiac action potential and leading to QT interval prolongation, the lack of knowledge regarding chemical structures in drugs that may induce the prolongation of the QT interval remains a barrier to further understanding the underlying mechanism and developing an effective prediction strategy. In this study, we thoroughly investigated the differences in chemical structures between QT-prolonging drugs and drugs with no drug-induced QT prolongation (DIQT) concerns, based on the Drug-Induced QT Prolongation Atlas (DIQTA) dataset. Three categories of structural alerts (SAs), namely amines, ethers, and aromatic compounds, appeared in large quantities in QT-prolonging drugs, but rarely in drugs with no DIQT concerns, indicating a close association between SAs and the risk of DIQT. Moreover, using the molecular descriptors associated with these three categories of SAs as features, the structure–activity relationship (SAR) model for predicting the high risk of inducing QT interval prolongation of marketed drugs achieved recall rates of 72.5% and 80.0% for the DIQTA dataset and the FDA Adverse Event Reporting System (FAERS) dataset, respectively. Our findings may promote a better understanding of the mechanism of DIQT and facilitate research on cardiac adverse drug reactions in drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry, Sichuan University, Chengdu 610064, China.
- Medical Big Data Center, Sichuan University, Chengdu 610064, China.
ORCID-Profile: Zhining Wen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Long, W., Li, S., He, Y., Lin, J., Li, M., & Wen, Z. (2023). Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076771
Vancouver
Long W, Li S, He Y, Lin J, Li M, Wen Z. Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076771
BibTeX
@article{Long2023,
author = {Long, Wulin and Li, Shihai and He, Yujie and Lin, Jinzhu and Li, Menglong and Wen, Zhining},
title = {Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076771}
}
EUVIMED